MX2020009642A - Anticuerpos monoclonales de interleucina-31 para uso veterinario. - Google Patents
Anticuerpos monoclonales de interleucina-31 para uso veterinario.Info
- Publication number
- MX2020009642A MX2020009642A MX2020009642A MX2020009642A MX2020009642A MX 2020009642 A MX2020009642 A MX 2020009642A MX 2020009642 A MX2020009642 A MX 2020009642A MX 2020009642 A MX2020009642 A MX 2020009642A MX 2020009642 A MX2020009642 A MX 2020009642A
- Authority
- MX
- Mexico
- Prior art keywords
- region
- seq
- amino acid
- acid residues
- sequence represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643940P | 2018-03-16 | 2018-03-16 | |
| PCT/US2019/014885 WO2019177697A2 (en) | 2018-03-16 | 2019-01-24 | Interleukin-31 monoclonal antibodies for veterinary use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009642A true MX2020009642A (es) | 2021-01-08 |
Family
ID=65363404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009642A MX2020009642A (es) | 2018-03-16 | 2019-01-24 | Anticuerpos monoclonales de interleucina-31 para uso veterinario. |
| MX2024015876A MX2024015876A (es) | 2018-03-16 | 2020-09-15 | Anticuerpos monoclonales de interleucina-31 para uso veterinario |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024015876A MX2024015876A (es) | 2018-03-16 | 2020-09-15 | Anticuerpos monoclonales de interleucina-31 para uso veterinario |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11530262B2 (de) |
| EP (1) | EP3765500A2 (de) |
| JP (2) | JP7449234B2 (de) |
| KR (3) | KR102828306B1 (de) |
| CN (1) | CN112020511B (de) |
| AU (1) | AU2019234220B2 (de) |
| BR (1) | BR112020017703A2 (de) |
| CA (1) | CA3093539A1 (de) |
| MX (2) | MX2020009642A (de) |
| WO (1) | WO2019177697A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| US11433139B2 (en) | 2018-03-16 | 2022-09-06 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| KR20230005875A (ko) * | 2020-04-22 | 2023-01-10 | 킨드레드 바이오사이언시스, 인코포레이티드 | 수의학 용도를 위한 장시간-작용성 항-il31 항체 |
| KR20230038522A (ko) | 2020-07-10 | 2023-03-20 | 인베티엑스 인코포레이티드 | 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법 |
| GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| TWI904261B (zh) | 2020-10-19 | 2025-11-11 | 美商碩騰服務公司 | 犬及貓抑瘤素Ｍ受體β之抗體及其用途 |
| WO2022109403A1 (en) * | 2020-11-23 | 2022-05-27 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| WO2022178201A1 (en) | 2021-02-22 | 2022-08-25 | Zoetis Services Llc | Horse il-31 induced pruritus model |
| KR20240139085A (ko) | 2022-02-09 | 2024-09-20 | 펫메딕스 리미티드 | 치료 항체 |
| WO2024145280A2 (en) | 2022-12-27 | 2024-07-04 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| AU2024210302A1 (en) | 2023-01-20 | 2025-09-04 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| WO2024172083A1 (ja) * | 2023-02-17 | 2024-08-22 | 富士フイルム株式会社 | 細胞の製造方法、多重特異性抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの製造方法 |
| CN117186220A (zh) * | 2023-07-20 | 2023-12-08 | 北京伟杰信生物科技有限公司 | 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用 |
| CN120865401A (zh) * | 2023-11-27 | 2025-10-31 | 宁波贝安生物科技有限公司 | 抗il-31的抗体及其用途 |
| GB202405576D0 (en) * | 2024-04-19 | 2024-06-05 | 272Bio Ltd | VHH antibodies |
| CN121108334A (zh) * | 2024-06-11 | 2025-12-12 | 优迈生物科技(连云港)有限公司 | 抗犬il-31的抗体及其应用 |
| CN118599004B (zh) * | 2024-06-11 | 2024-11-26 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种抗猫IgG单克隆抗体或其抗原结合片段及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350576A (en) | 1991-09-13 | 1994-09-27 | Mycogen Corporation | Bacillus thuringiensis isolates for controlling acarides |
| US6194167B1 (en) | 1997-02-18 | 2001-02-27 | Washington State University Research Foundation | ω-3 fatty acid desaturase |
| MXPA01009363A (es) | 1999-03-18 | 2002-06-04 | Merck Patent Gmbh | Proteina para bloquear la adhesion de plaquetas. |
| EP1130098A3 (de) | 2000-02-29 | 2003-09-10 | Pfizer Products Inc. | Säugetier Osteoreguline |
| ATE402192T1 (de) | 2000-03-03 | 2008-08-15 | Kyowa Hakko Kogyo Kk | Anti-ccr4 antikörper und fragmente davon |
| KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| US6818444B2 (en) | 2000-08-04 | 2004-11-16 | Heska Corporation | Canine and feline proteins, nucleic acid molecules and uses thereof |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| US7261890B2 (en) | 2001-12-21 | 2007-08-28 | Idexx Laboratories, Inc. | Methods for using canine immunoglobulin variable domains and caninized antibodies |
| US20040208870A1 (en) | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| JP2008528039A (ja) | 2005-01-28 | 2008-07-31 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１の均質調製物 |
| EP1858924A1 (de) | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Verfahren zur behandlung von hauterkrankungen mit einem il-31ra-antagonisten |
| WO2006088955A2 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| US20070098715A1 (en) | 2005-03-25 | 2007-05-03 | Seth Ettenberg | Antibodies against the tenascin major antigens |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| KR101443050B1 (ko) | 2005-05-06 | 2014-09-22 | 지모제넥틱스, 인코포레이티드 | Ｉｌ-31 단클론성 항체 및 사용법 |
| EP2749571A3 (de) | 2006-01-10 | 2014-08-13 | ZymoGenetics, Inc. | Verfahren zur Behandlung von Schmerzen und Entzündungen in Nervengewebe mithilfe von IL-31RA- und OSMRb-Antagonisten |
| JP5230022B2 (ja) | 2006-08-09 | 2013-07-10 | ベイラー リサーチ インスティテュート | 抗インターフェロンアルファモノクローナル抗体及び使用方法 |
| ES2548714T3 (es) | 2006-09-01 | 2015-10-20 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y procedimientos de uso |
| ME03057B (de) | 2007-12-07 | 2019-01-20 | Zymogenetics Inc | Für IL-31 spezifische humanisierte Antikörpermoleküle |
| KR101335843B1 (ko) | 2008-08-20 | 2013-12-02 | 조에티스 엘엘씨 | 피롤로[2,3-ｄ]피리미딘 화합물 |
| WO2011065935A1 (en) | 2009-11-24 | 2011-06-03 | Cornell University | Methods for monoclonal antibody production |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| BR112012008833A2 (pt) | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CA2875783C (en) | 2012-06-06 | 2018-12-11 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
| KR102257305B1 (ko) | 2013-03-28 | 2021-05-28 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 미세유동 장치 및 분비물의 다세포 검정법에서의 그의 사용 방법 |
| EP3517625B1 (de) | 2014-05-22 | 2021-01-20 | The University of British Columbia | Verfahren zur bestimmung von lymphozyt-rezeptor-kettenpaaren |
| CA2974632A1 (en) | 2015-02-04 | 2016-08-11 | The University Of British Columbia | Methods and devices for analyzing particles |
| JP6987744B2 (ja) * | 2015-09-08 | 2022-01-05 | ウニヴェルズィテート チューリッヒ | 虫刺され過敏症の治療 |
| BR112018071965A2 (pt) | 2016-04-27 | 2019-03-06 | Benchmark Animal Health Ltd | tratamento da dermatite atópica canina |
| WO2018162577A1 (en) | 2017-03-07 | 2018-09-13 | Universität Zürich | Treatment of pruritus in horses |
| WO2019086694A1 (en) | 2017-11-06 | 2019-05-09 | Geert Mudde | Il31 antigen and vaccine |
-
2019
- 2019-01-24 CA CA3093539A patent/CA3093539A1/en active Pending
- 2019-01-24 CN CN201980026306.5A patent/CN112020511B/zh active Active
- 2019-01-24 KR KR1020237033543A patent/KR102828306B1/ko active Active
- 2019-01-24 AU AU2019234220A patent/AU2019234220B2/en active Active
- 2019-01-24 KR KR1020207029611A patent/KR102587633B1/ko active Active
- 2019-01-24 MX MX2020009642A patent/MX2020009642A/es unknown
- 2019-01-24 US US16/256,223 patent/US11530262B2/en active Active
- 2019-01-24 JP JP2020549618A patent/JP7449234B2/ja active Active
- 2019-01-24 WO PCT/US2019/014885 patent/WO2019177697A2/en not_active Ceased
- 2019-01-24 EP EP19704523.0A patent/EP3765500A2/de active Pending
- 2019-01-24 KR KR1020257004141A patent/KR20250026872A/ko active Pending
- 2019-01-24 BR BR112020017703-2A patent/BR112020017703A2/pt unknown
-
2020
- 2020-09-15 MX MX2024015876A patent/MX2024015876A/es unknown
-
2022
- 2022-01-07 US US17/571,117 patent/US12084494B2/en active Active
-
2024
- 2024-02-29 JP JP2024029468A patent/JP7746436B2/ja active Active
- 2024-08-08 US US18/798,132 patent/US20250136677A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3093539A1 (en) | 2019-09-19 |
| KR20230145511A (ko) | 2023-10-17 |
| AU2019234220B2 (en) | 2025-09-11 |
| KR102828306B1 (ko) | 2025-07-01 |
| JP7746436B2 (ja) | 2025-09-30 |
| JP7449234B2 (ja) | 2024-03-13 |
| RU2020129449A (ru) | 2022-04-18 |
| BR112020017703A2 (pt) | 2021-03-09 |
| KR102587633B1 (ko) | 2023-10-10 |
| JP2024063118A (ja) | 2024-05-10 |
| US20220127351A1 (en) | 2022-04-28 |
| CN112020511B (zh) | 2025-07-04 |
| RU2020129449A3 (de) | 2022-04-18 |
| KR20250026872A (ko) | 2025-02-25 |
| KR102587633B9 (ko) | 2025-04-15 |
| EP3765500A2 (de) | 2021-01-20 |
| US11530262B2 (en) | 2022-12-20 |
| WO2019177697A2 (en) | 2019-09-19 |
| WO2019177697A9 (en) | 2020-04-02 |
| US20190284272A1 (en) | 2019-09-19 |
| AU2019234220A1 (en) | 2020-09-10 |
| MX2024015876A (es) | 2025-02-10 |
| WO2019177697A3 (en) | 2019-10-31 |
| US20250136677A1 (en) | 2025-05-01 |
| US12084494B2 (en) | 2024-09-10 |
| KR20200132949A (ko) | 2020-11-25 |
| CN112020511A (zh) | 2020-12-01 |
| JP2021518117A (ja) | 2021-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009642A (es) | Anticuerpos monoclonales de interleucina-31 para uso veterinario. | |
| CO2019012356A2 (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso | |
| CY1123791T1 (el) | Μονοκλωνικο αντισωμα ιντερλευκινης-31 | |
| CL2017001866A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| CL2020001619A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095) | |
| PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| AR108377A1 (es) | Proteínas de unión biespecíficas y sus usos | |
| CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| PE20141162A1 (es) | Anticuerpos anti-il-23 | |
| PE20230108A1 (es) | Variantes de anticuerpos caninos | |
| PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| EA200701363A1 (ru) | Антитела против il-12, эпитопы, композиции, способы и применения | |
| CL2021002727A1 (es) | Vacuna con subunidades del vfpc | |
| MX2025011262A (es) | Vacunas de peptidos contra interleucina-31 | |
| CL2021000942A1 (es) | Anticuerpos anti-npr1 y usos relacionados. | |
| EA202092457A1 (ru) | Доставка антител к fam19a5 с помощью аденоассоциированного вируса (aav) | |
| BR112022014574A2 (pt) | Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença | |
| EA201691782A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| UA120048C2 (uk) | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) | |
| AR118763A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| MX2021002299A (es) | Anticuerpos de anti-cd33 y metodos para usarlos. | |
| MX2021012488A (es) | Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos. | |
| JOP20200215A1 (ar) | الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها | |
| BR112021024938A2 (pt) | Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso | |
| CO2025017440A2 (es) | Anticuerpos de dominio único modificados |